← Back to Home

Another path to organ preservation in rectal cancer: dostarlimab receives FDA accelerated approval

For patients with locally advanced rectal cancer and specific DNA repair abnormalities, immunotherapy makes avoiding surgery, chemotherapy, and radiation possible. However, assessments of sustained complete response still differ, and organ preservation also means long-term follow-up.

By SURL BioNews

For patients undergoing rectal cancer treatment, what matters is not only whether the tumor disappears, but also whether they can maintain their way of life afterward. Surgery, radiation therapy, and chemotherapy can control the disease, but may also leave patients with bowel, urinary, or sexual dysfunction. On October 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new indication for the immunotherapy drug dostarlimab (brand name Jemperli), providing another organ-preserving treatment option for a group of adult patients with specific tumor biomarkers.

The approval covers stage II and III locally advanced rectal cancer, with tumors confirmed by an FDA-authorized test to have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These tumors have an impaired ability to repair DNA errors, making them prone to accumulating mutations and more likely to respond to immunotherapy. Dostarlimab is an antibody that blocks PD-1, relieving some immune suppression and helping immune cells attack cancer cells; this approval does not apply to all rectal cancers.

The main evidence supporting the decision came from the phase II AZUR-1 trial, which enrolled 154 previously untreated patients. This was a multicenter, single-arm, open-label study, with no direct comparison against conventional therapies. Patients received a 500-milligram intravenous infusion every three weeks for up to nine cycles, followed by assessments of treatment efficacy using examinations including endoscopy, rectal magnetic resonance imaging, and computed tomography.

The key endpoint was whether a “clinical complete response” could be maintained for 12 months—in other words, whether the absence of a detectable tumor on clinical examinations could persist. According to the investigator assessment released by GSK, 98 of 144 evaluable patients met this endpoint, or 68%; independent central review found that 54 of 116 patients did so, or 47%. Both the numbers of patients available for analysis and the results differed between the two assessments. Another 38 patients whose complete responses were confirmed by central review had not yet accumulated 12 months of follow-up. These figures cannot be directly interpreted as cure rates.

Whether patients avoided other treatments is another outcome closely tied to their daily lives. FDA data showed that 110 of the 154 patients, approximately 71%, had received only dostarlimab as of the data cutoff, with no additional treatment and no disease progression; another 26 underwent surgery, and 13 received additional systemic therapy or radiation therapy. Immunotherapy therefore did allow some patients to avoid conventional treatment for the time being, but some still needed subsequent intervention.

Organ preservation does not mean the end of medical care. Under the trial protocol, patients who achieved a clinical complete response and entered nonoperative management underwent recurrence assessments using multiple methods every four months for the first two years, then every six months. If a complete response was not achieved, or if the disease recurred or progressed, investigators assessed the use of standard treatment. At the core of this approach, treatment response and close monitoring jointly determine the next step.

Immunotherapy itself also carries risks. GSK said that 20% of patients in the trial experienced serious adverse reactions, and 3% permanently discontinued treatment because of adverse reactions; common reactions included fatigue, rash, diarrhea, and itching. The FDA also noted that the drug carries warnings for immune-mediated adverse reactions and infusion-related reactions, among others. Avoiding surgery, chemotherapy, or radiation still does not mean avoiding the burden of treatment.

Median follow-up in AZUR-1 now exceeds two years, and GSK said that no disease recurrence had been reported among patients who responded to treatment. However, these remain interim data that continue to accumulate, and a single-arm study cannot directly answer whether long-term survival is better than with other strategies. Accelerated approval gives eligible patients earlier access to a new option; whether it can provide lasting cancer control while preserving organs and function still requires confirmation through further follow-up. The manufacturer must also continue collecting data to establish durable clinical benefit.

References

  1. FDA
  2. FDA
  3. GSK
  4. The ASCO Post